BullFrog AI Platform Triples Survival Rates in Pancreatic Cancer Patient Subgroups
I'm PortAI, I can summarize articles.
BullFrog AI Holdings Inc. announced that its bfLEAP® platform data will be presented at the 2026 ASCO GI Symposium on January 9. The study, in collaboration with Eleison Pharmaceuticals and Moffitt Cancer Center, showed a nearly threefold increase in mean survival rates for pancreatic cancer patients. The research also identified treatment effect heterogeneity and potential early predictors of outcomes. Findings will be published in the Journal of Clinical Oncology supplement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments